Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714252 | 1.00 | CYP2A6 (0.50) | CYP2A6DYRK1AHSP90AA1PTPRCPTPN6 | |
| SCHEMBL28744566 | 0.94 | CYP2A6 (0.50) | CYP2A6DYRK1AHSP90AA1PTPRCPTPN6 | |
| SCHEMBL29263832 | 0.84 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL25061130 | 0.83 | DYRK1A (0.58) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL20984002 | 0.83 | DYRK1A (0.58) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL405354 | 0.81 | CYP2A6 (0.41) | CYP2A6DYRK1AHSP90AA1KDM4EMEN1 | |
| SCHEMBL30623084 | 0.81 | CYP2A6 (0.41) | CYP2A6DYRK1AHSP90AA1KDM4EMEN1 | |
| SCHEMBL20180340 | 0.78 | DYRK1A (0.53) | CYP2A6DYRK1ACA2CA12MEN1 | |
| SCHEMBL28745027 | 0.76 | CYP2A6 (0.37) | CYP2A6DYRK1AHSP90AA1PTPRCPTPN6 | |
| SCHEMBL164774 | 0.73 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 910 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059955-A | Imidazo pyridone compound, photocatalysis continuous synthesis method and application thereof | 南京工业大学 | 2026-05-19 | — | — | CN | claimed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | claimed |
| CN-114853795-A | Arylboron compound of conjugated olefin and preparation method and application thereof | 南京工业大学 | 2022-08-05 | — | — | CN | claimed |
| CN-114656502-A | Water-soluble aggregation-induced emission photosensitizer and preparation method thereof | 华东理工大学 | 2022-06-24 | — | — | CN | claimed |
| EP-4142874-B1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-20260084134-A1 | STORAGE AND DELIVERY OF GASEOUS CHEMICAL REACTANTS IN CHEMICAL PROCESSES USING METAL-ORGANIC FRAMEWORKS | UNIV CORNELL (US) | 2026-03-26 | — | — | US | disclosed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025244832-A1 | NOVEL AMINOGUANIDINE DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | KONG'S PHARMACEUTICAL CO. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4650002-A1 | ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) | Ludwig-Maximilians-Universität (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-12459912-B2 | Advantageous benzothiophene compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-11-04 | — | — | US | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0560554-A2 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| US-5169860-A | Benzofuran or benzothiophene arylsulfonylureas | ELI LILLY AND COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0129478-B1 | 2-SULFAMOYLBENZO (B) THIOPHENE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4788192-A | TOPICALLY APPLYING; FOR GLAUCOMA | MERCK & CO., INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4668697-A | Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0129478-A2 | 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | CYP2A6 495/4885DYRK1A 3517/4885HSP90AA1 1899/4885 |
| US-20260084134-A1 | STORAGE AND DELIVERY OF GASEOUS CHEMICAL REACTANTS IN CHEMICAL PROCESSES USING METAL-ORGANIC FRAMEWORKS | ME3, ME2, SLC25A11 | CYP2A6 1626/4885DYRK1A 4740/4885HSP90AA1 2381/4885 |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CYP2A6 1062/4885DYRK1A 3701/4885HSP90AA1 776/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | CYP2A6 51/4885DYRK1A 3559/4885HSP90AA1 339/4885 |
| US-12459912-B2 | Advantageous benzothiophene compositions for mental disorders or enhancement | SLC6A3, CREBBP, SLC1A2 | CYP2A6 1879/4885DYRK1A 1082/4885HSP90AA1 1683/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | CYP2A6 284/4885DYRK1A 1592/4885HSP90AA1 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.